We are live on ! Find out more
IBER.U

Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant

Delisted

IBER.U was delisted on the 1st of March, 2023.

34 hedge funds and large institutions have $52.4M invested in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

43% less funds holding

Funds holding: 6034 (-26)

56% less capital invested

Capital invested by funds: $120M → $52.4M (-$67.7M)

96% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 26

Holders
34
Holders Change
-26
Holders Change %
-43.33%
% of All Funds
0.59%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
1
Increased
6
Reduced
8
Closed
26
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
WA
51
Whitebox Advisors
Minnesota
-$740K -75,000 Closed
WRBC
52
W.R. Berkley Corp
Connecticut
-$678K -68,776 Closed
AM
53
Ampfield Management
New York
-$593K -60,100 Closed
Goldman Sachs
54
Goldman Sachs
New York
-$540K -54,762 Closed
PI
55
PEAK6 Investments
Illinois
-$493K -50,000 Closed
DMK
56
David M. Knott
-$355K -36,000 Closed
Capstone Investment Advisors
57
Capstone Investment Advisors
New York
-$246K -25,000 Closed
BCM
58
Brigade Capital Management
New York
-$197K -20,000 Closed
PCM
59
Prelude Capital Management
New York
-$99K -10,000 Closed
UBS Group
60
UBS Group
Switzerland
-$8K -840 Closed

IBER.U Hedge Fund Activity: Q2 2021 in Review

34 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) for Q2 2021, worth a combined $52.4M — down 56% from $120M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of IBER.U and 1 opened new positions — a net loss of 25 holders — while 8 trimmed existing stakes and 6 added.

The largest buyer was D.E. Shaw & Co, adding an estimated $306K. The largest seller was Citadel Advisors, cutting an estimated $5.47M.

  • 34 institutional investors held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) as of Q2 2021, down from 60 in Q1 2021.
  • Funds reported $52.4M of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant stock for Q2 2021, down 56% quarter-over-quarter.
  • 1 fund opened new Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant positions in Q2 2021 and 26 closed out, a net change of -25 holders.
  • The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant buyer in Q2 2021 was D.E. Shaw & Co, an estimated $306K added.
  • The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant seller in Q2 2021 was Citadel Advisors, an estimated $5.47M sold.

Based on aggregated 13F filings for Q2 2021.